medigraphic.com
ISSN 0210-5187 (Electronic)

2018, Number 2

<< Back Next >>

Med Cutan Iber Lat Am 2018; 46 (2)

Melasma and quality of life: prospective and descriptive clinical study of 142 patients

Jiménez RPX, Medina CDE

Language: Spanish
References: 25
Page: 104-111
PDF size: 323.63 Kb.


ABSTRACT

Transversal and descriptive prospective clinical study aimed at evaluating the quality of life in patients with melasma. Material and methods: Patients with melasma diagnosis in Dermatology Service of HGR 220 IMSS in Toluca, Mexico. Measuring instruments: index of quality of life in dermatology (IDQL), melasma severity scale (MASI), scale quality of life for patients with melasma (MELASQOL). This study included informed consent. Statistical analysis measures of central tendency and standard deviation were used statistical package Microsoft Office Excel 2007. Results: Of 142 patients diagnosed with melasma, only 103 completed the study; 100% were women, with a mean age of 36 ± 10 years, the most frequent low socioeconomic status was 57 cases (55.3%) the most frequent secondary education was 42 patients (42.7%) and 23 units Family Medicine reference, Toluca gave 42 patients (40.8%) in five months. Phototype predominant type IV with 55 patients (53.4%). Epidermal melasma type was 67 patients (65%). The region centrofacial 66 cases (64.1%). Time evolution more than five years, 42 patients (40.8%). The severity of the most common melasma was moderate, with 42 patients 40.8%. Quality of life was affected slightly in our group of patients in about half of cases; 49 cases (47.6%) according to DQLI and 59 patients (57.3%) with the MELASQOL scale. Conclusions: Melasma is frequent in women hyperchromia. Affected the quality of life in our study was mild, melasma diagnosis is easy, it is a cosmetic disease type in order of importance to patients; sent prefer their specialist consultation when they have other symptomatic disease.


REFERENCES

  1. Halioua B, Beumont MG, Lunel F. Quality of life in dermatology. Int J Dermatol. 2000; 39 (11): 801-806.

  2. Hernández-Fernaud E, Hernández-Ruiz B, Ruiz A, Rodríguez-Pérez A, Betancor-Rodríguez V. Impacto de las alteraciones dermatológicas de baja expresión en función del nivel de especificidad de la calidad de vida. Psicothema. 2008; 20 (2): 273-278.

  3. Deyo RA. The quality of life, research, and care. Ann Intern Med. 1991; 114 (8): 695-697.

  4. Velarde-Jurado E, Avila-Figueroa C. Evaluación de la calidad de vida. Salud Pública Méx. 2002; 44 (4): 349-361.

  5. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med. 1993; 118 (8): 622-629.

  6. Arenas R. Melasma. Atlas de Dermatología. 3a edición. México, D.F.: McGraw Hill Interamericana; 2005. p. 116.

  7. Balkrishnan R, Kelly AP, McMichael A, Torok H. Improved quality of life with effective treatment of facial melasma: the pigment trial. J Drugs Dermatol. 2004; 3 (4): 377-381.

  8. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA. 1995; 273 (1): 59-65.

  9. Alcalá-Pérez D, Espinosa-Villaseñor N, Jurado-Santa Cruz F. Melasma en hombres. Rev Cent Dermatol Pascua. 2015; 24 (1): 14-20.

  10. Fitzpatrick R, Fletcher A, Gore S, Jones D, Spiegelhalter D, Cox D. Quality of life measures in health care. I: Applications and issues in assessment. BMJ. 1992; 305 (6861): 1074-1077.

  11. Bandyopadhyay D. Topical treatment of melasma. Indian J Dermatol. 2009; 54 (4): 303-309.

  12. Balkrishnan R, McMichael AJ, Hu JY, Camacho FT, Shew KR, Bouloc A et al. Correlates of health-related quality of life in women with severe facial blemishes. Int J Dermatol. 2006; 45 (2): 111-115.

  13. Jurado-Santa Cruz F, Villaseñor-Camacho GP, Peralta-Pedrero ML, Rodríguez-Acar M, Morales-Sánchez M. Calidad de vida en hombres con melasma. Rev Cent Dermatol Pascua. 2013; 22 (3): 94-99.

  14. Perez M, Luke J, Rossi A. Melasma in Latin Americans. J Drugs Dermatol. 2011; 10 (5): 517-523.

  15. Kalus AA, Chien AJ, Olerud JE. Estrógenos y piel: en dermatología en medicina general. 5a edición. Ed. Médica Panamericana; Barcelona: 2009. pp. 1479-1481.

  16. Sheth VM, Pandya AG. Melasma: a comprehensive update: part I. J Am Acad Dermatol. 2011; 65 (4): 689-697.

  17. Singh G, Chatterjee M, Grewal R, Verma R. Incidence and care of environmental dermatoses in the high-altitude region of ladakh, India. Indian J Dermatol. 2013; 58 (2): 107-112.

  18. Instituto Nacional de Estadística y Geografía. México. Mapa con elevaciones principales. Consultado el 13-05-2012.

  19. Achar A, Rathi SK. Melasma: a clinico-epidemiological study of 312 cases. Indian J Dermatol. 2011; 56 (4): 380-382.

  20. Del Rosario E, Florez-Pollack S, Zapata L Jr, Hernandez K, Tovar-Garza A, Rodrigues M et al. Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma. J Am Acad Dermatol. 2018; 78 (2): 363-369.

  21. Jang YH, Sim JH, Kang HY, Kim YC, Lee ES. The histopathological characteristics of male melasma: comparison with female melasma and lentigo. J Am Acad Dermatol. 2012; 66 (4): 642-649.

  22. Kang HY, Bahadoran P. Application of in vivo reflectance confocal microscopy in melasma classification. J Am Acad Dermatol. 2012; 67 (1): 157; author reply 157-158.

  23. Morgan M, McCreedy R, Simpson J, Hay RJ. Dermatology quality of life scales--a measure of the impact of skin diseases. Br J Dermatol. 1997; 136 (2): 202-206.

  24. Pandya AG, Hynan LS, Bhore R, Riley FC, Guevara IL, Grimes P et al. Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method. J Am Acad Dermatol. 2011; 64 (1): 78-83, 83.e1-2.

  25. Cestari TF, Hexsel D, Viegas ML, Azulay L, Hassun K, Almeida AR et al. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL-BP study and improvement of QoL of melasma patients after triple combination therapy. Br J Dermatol. 2006; 156 Suppl 1: 13-20.




2020     |     www.medigraphic.com